Dechert Advised Lysogene in a Successful Private Placement in Unprecedented Market Conditions
March 27, 2020
Dechert LLP advised Lysogene S.A., a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, in connection with its successful capital increase in challenging market conditions.
The placement was led by a leading US life sciences Investor, and complemented by a US tier1 Investor and existing shareholder as well as an Industrial Partner of Lysogene.
The proceeds from the capital increase are expected to be used to fund the phase 1-3 clinical trial of LYS-GM101 for the treatment of GM1 gangliosidosis, the commercial launch preparation in Europe of the LYS-SAF302 in MPSIIIA and the company’s corporate expenses.
The Dechert LLP team, coordinated by Alain Decombe, advised Lysogene on legal aspects and involved:
- in London: partner Patrick Lyons and associate Nick Quarrie; and
- in Paris: counsel Sophie Lafay and associates Anne-Sophie Gallot and Charlotte Torck.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
